Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

President Trump published letters to 17 major pharma companies reiterating his requirements for them to fulfill his MFN order ...

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

Viridian Therapeutics partners with Kissei Pharmaceutical to advance treatments for thyroid eye disease in Japan, enhancing patient care and market potential.

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Aetna enhances user experience with AI-driven Care Paths, simplifying health navigation and personalizing care for members ...

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...

In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.